Who is sponsoring NCT02095158?

NCT02095158 is sponsored by Allergan.

What condition does NCT02095158 study?

NCT02095158 studies Erythema, Rosacea.

What drugs are being tested in NCT02095158?

Interventions: Oxymetazoline HCL Cream 1.0%.

What is the status of NCT02095158?

NCT02095158 is currently COMPLETED.

Last reviewed 2019-11-15 · How we verify

A Long-term Safety and Efficacy Study of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea

NCT02095158 Phase 3 COMPLETED Results posted

This study will evaluate the long-term safety and efficacy of oxymetazoline hydrogen chloride (HCL) Cream 1.0% (AGN-199201) in patients with persistent erythema associated with rosacea.

Details

Lead sponsor	Allergan
Phase	Phase 3
Status	COMPLETED
Enrolment	440
Start date	2014-04
Completion	2015-09

Conditions

Erythema
Rosacea

Interventions

Oxymetazoline HCL Cream 1.0%

Primary outcomes

Percentage of Participants With Treatment-Related Adverse Events — 56 Weeks
An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A Treatment-Related Adverse Event is an Adverse Event determined by the investigator to be causally related to the study medication.

Countries

United States